Disposable Perfusion Phantom for Accurate DCE (Dynamic Contrast Enhanced)-MRI Measurement of Pancreatic Cancer Therapy Response

NCT04588025 | Recruiting

• 1 other identifier: PENDING
• Study Type: interventional
• Target: 55
• Locations: 1 country
• Sites: 2

Brief Summary

The goal of this study is to investigate whether the therapeutic response of pancreatic tumors can be accurately assessed using quantitative DCE-MRI, when the inter/intra-scanner variability is reduced using the Point-of-care Portable Perfusion Phantom, P4. The intra-scanner variability over time leads to errors in therapy monitoring, while the inter-scanner variability impedes the comparison of data among institutes. The P4 is small enough to be imaged concurrently in the bore of a standard MRI scanner with a patient for real-time quality assurance. The P4 is safe, inexpensive and easily operable, thus it has great potential for widespread and routine clinical use for accurate diagnosis, prognosis and therapy monitoring. This study has identified two arms, one arm is healthy individuals that will undergo DCE MRI at three different MRI locations to establish baseline results. The healthy volunteers will undergo these MRIs prior to the second arm, which contains patients with pancreatic cancer. The pancreatic cancer patients will only have DCE MRI done at one location.

Conditions

Pancreatic Cancer

Outcome Measures

Primary Outcomes (5)

• Reproducibility of quantitative DCE-MRI measurement with MRI 1.

  This outcome is assigned to the 5 healthy volunteers that we will be evaluated on 3 different MRIs. Two scans will be done to establish baseline measures.

  Baseline

• Reproducibility of quantitative DCE-MRI measurement with MRI 2.

  This outcome is assigned to the 5 healthy volunteers that we will be evaluated on 3 different MRIs.

  Baseline to 3-days (MRI number 2)

• Reproducibility of quantitative DCE-MRI measurement with MRI 3.

  This outcome is assigned to the 5 healthy volunteers that we will be evaluated on 3 different MRIs.

  Baseline to 7-days (MRI number 3)

• Measure change in blood flow within the pancreatic cancer as measured by the P4.

  This is being done before therapy has been initiated and is being measured by the P4 during an MRI scan. The results will help determine if undergoing therapy is effective by measuring the change in blood flow and help to decide if we need to continue the current therapy or change to a different one. Blood flow often serves as a critical indicator showing a disease status.

  Baseline

• Measure change in blood flow within the pancreatic cancer as measured by the P4.

  This is being done after therapy has been initiated and is being measured by the P4 during an MRI scan. The results will help determine if undergoing therapy is effective by measuring the change in blood flow and help to decide if we need to continue the current therapy or change to a different one. Blood flow often serves as a critical indicator showing a disease status.

  6 weeks post-therapy

Study Arms (2)

Healthy Volunteers

ACTIVE COMPARATOR

Device: Point-of-care Portable Perfusion Phantom, P4

Pancreatic Cancer Participants

ACTIVE COMPARATOR

Device: Point-of-care Portable Perfusion Phantom, P4

Interventions

Point-of-care Portable Perfusion Phantom, P4 DEVICE

P4 is a perfusion phantom developed by Dr. Harrison Kim that can significantly reduce variation in quantitating perfusion of human abdominal tissues across MRI scanners.

Healthy Volunteers; Pancreatic Cancer Participants

Eligibility Criteria

• Age: 19 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Targeted/planned enrollment in the study will include all racial/ethnic groups with no groups excluded on the basis of race, ethnicity or gender.
• Participants should be 19 years of age or older
• Participants should not have any known major health problems including but not limited to cancers, heart diseases, diabetes, high blood pressure and/or cholesterol, stroke, respiratory problems, and arthritis.

You may not qualify if:

• Participants having any known major health problems will be excluded.
• Participants with safety contraindications to MRI examination (determined by standard clinical screening).
• Participants on hemodialysis or with acute renal failure will be excluded. (Participants on hemodialysis and those with renal failure who receive intravenous gadolinium may be at increased risk for a condition called Nephrogenic systemic fibrosis/ Nephrogenic fibrosing dystrophy and thus will be excluded.)
• Participants may not be pregnant or lactating.
• Participants may not father a child while on this study as the treatment may indirectly affect an unborn child.
• Unless participants cannot have children because of surgery or other medical reasons, participants must have been using an effective form of birth control before starting the study.
• Participants must also agree to continue to use an effective form of birth control for 6 months after taking the study. Effective birth control includes birth control pills, patch, IUD (intrauterine device), condom, sponge, diaphragm with spermicide, or avoiding sexual activity that could cause pregnancy.
• Pancreatic Cancer Participants:
• Patients having biopsy proven locally advanced pancreatic cancer will be asked to participate in this study.
• Targeted/planned enrollment in the study will include all racial/ethnic groups, with no groups excluded on the basis of race, ethnicity or gender.
• Participants should be 19 years of age or older.
• Participants with safety contraindications to MRI examination (determined by standard clinical screening).
• Participants on hemodialysis or with acute renal failure will be excluded.
• Participants on hemodialysis and those with renal failure who receive intravenous gadolinium may be at increased risk for a condition called Nephrogenic systemic fibrosis/ Nephrogenic fibrosing dystrophy and thus will be excluded.
• Participants may not be pregnant or lactating.

Sponsors & Collaborators

• Ohio State University: lead

Study Sites (2)

The Ohio State University

Columbus, Ohio, 43210, United States

RECRUITING

Vanderbilt University Medical Center

Nashville, Tennessee, 37232, United States

RECRUITING

MeSH Terms

Conditions

Pancreatic Neoplasms

Condition Hierarchy (Ancestors)

Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Endocrine Gland Neoplasms; Digestive System Diseases; Pancreatic Diseases; Endocrine System Diseases

Study Officials

• Harrison Kim, PhD

  Ohio State University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Harrison Kim, PhD

CONTACT

614-293-8315; Harrison.Kim@osumc.edu

Tamara Stein, MPH

CONTACT

614-293-8315; Tamara.Stein@osumc.edu

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Model Details: The healthy group is going to be the group to establish a baseline for the pancreatic group.

Study Record Dates

• First Submitted: October 7, 2020
• First Posted: October 19, 2020
• Study Start: October 14, 2020
• Primary Completion (Estimated): October 1, 2026
• Study Completion (Estimated): October 1, 2027
• Last Updated: February 27, 2026

Record last verified: 2025-09

Data Sharing

• IPD Sharing: Will not share

Locations

US (2)